- Home
- GLXG vs IMRN Comparison
GLXG vs IMRN Comparison
Compare GLXG & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLXG
- IMRN
- Stock Information
- Founded
- GLXG 2013
- IMRN 1994
- Country
- GLXG Hong Kong
- IMRN Australia
- Employees
- GLXG N/A
- IMRN N/A
- Industry
- GLXG
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- GLXG
- IMRN Health Care
- Exchange
- GLXG NYSE
- IMRN Nasdaq
- Market Cap
- GLXG 11.1M
- IMRN 9.2M
- IPO Year
- GLXG 2024
- IMRN N/A
- Fundamental
- Price
- GLXG $0.55
- IMRN $1.70
- Analyst Decision
- GLXG
- IMRN Strong Buy
- Analyst Count
- GLXG 0
- IMRN 1
- Target Price
- GLXG N/A
- IMRN $5.00
- AVG Volume (30 Days)
- GLXG 73.0K
- IMRN 53.0K
- Earning Date
- GLXG 06-17-2025
- IMRN 06-17-2025
- Dividend Yield
- GLXG N/A
- IMRN N/A
- EPS Growth
- GLXG N/A
- IMRN N/A
- EPS
- GLXG N/A
- IMRN N/A
- Revenue
- GLXG $3,711,233.00
- IMRN $4,048,286.00
- Revenue This Year
- GLXG N/A
- IMRN N/A
- Revenue Next Year
- GLXG N/A
- IMRN N/A
- P/E Ratio
- GLXG N/A
- IMRN N/A
- Revenue Growth
- GLXG N/A
- IMRN 82.90
- 52 Week Low
- GLXG $0.52
- IMRN $1.50
- 52 Week High
- GLXG $16.93
- IMRN $2.87
- Technical
- Relative Strength Index (RSI)
- GLXG N/A
- IMRN 43.37
- Support Level
- GLXG N/A
- IMRN $1.69
- Resistance Level
- GLXG N/A
- IMRN $1.89
- Average True Range (ATR)
- GLXG 0.00
- IMRN 0.17
- MACD
- GLXG 0.00
- IMRN -0.01
- Stochastic Oscillator
- GLXG 0.00
- IMRN 34.06
About GLXG GALAXY PAYROLL GROUP LTD
Galaxy Payroll Group Ltd provides payroll outsourcing, employment, consultancy, and market research services based in Hong Kong. Its client base includes retail, trading, industrial, IT, financial, and professional services industries. Geographically, the company derives maximum revenue from its clients in the People's Republic of China and the rest from Hong Kong, Macau, Taiwan, Japan, Thailand, Singapore, and other countries.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.